Report from the 100th Cardiovascular and Renal Drugs Advisory Committee meeting: US Food and Drug Administration: December 8-9, 2003 Gaithersburg, MD
about
Aspirin under fire: aspirin use in the primary prevention of coronary heart diseaseAspirin for primary cardiovascular prevention: when is it worth the risks?Reconsidering low-dose aspirin therapy for cardiovascular disease: a study protocol for physician and patient behavioral change.Clinical research in primary stroke prevention: needs, opportunities, and challenges.Ranolazine: new approach for the treatment of stable angina pectoris.
P2860
Report from the 100th Cardiovascular and Renal Drugs Advisory Committee meeting: US Food and Drug Administration: December 8-9, 2003 Gaithersburg, MD
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Report from the 100th Cardiova ...... ber 8-9, 2003 Gaithersburg, MD
@ast
Report from the 100th Cardiova ...... ber 8-9, 2003 Gaithersburg, MD
@en
Report from the 100th Cardiova ...... ber 8-9, 2003 Gaithersburg, MD
@nl
type
label
Report from the 100th Cardiova ...... ber 8-9, 2003 Gaithersburg, MD
@ast
Report from the 100th Cardiova ...... ber 8-9, 2003 Gaithersburg, MD
@en
Report from the 100th Cardiova ...... ber 8-9, 2003 Gaithersburg, MD
@nl
prefLabel
Report from the 100th Cardiova ...... ber 8-9, 2003 Gaithersburg, MD
@ast
Report from the 100th Cardiova ...... ber 8-9, 2003 Gaithersburg, MD
@en
Report from the 100th Cardiova ...... ber 8-9, 2003 Gaithersburg, MD
@nl
P2093
P1433
P1476
Report from the 100th Cardiova ...... ber 8-9, 2003 Gaithersburg, MD
@en
P2093
Jeffrey S Borer
Paul W Armstrong
Steven E Nissen
Thomas Fleming
P304
P356
10.1161/01.CIR.0000118364.89571.16
P407
P577
2004-01-20T00:00:00Z